What is SGHT's current stock price?

SGHT (Sight Sciences, Inc.) is currently trading at $4.99 with a market cap of $271.7M.

What sector is Sight Sciences, Inc. in?

Sight Sciences, Inc. (SGHT) operates in the Healthcare sector, specifically in the Medical - Devices industry.

Is SGHT a good stock to buy?

Analysts have a Buy consensus on SGHT with a price target of $9.67. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

SGHT Sight Sciences, Inc.

Healthcare

$4.99+0.00%OpenMarket Cap: $271.7M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

5.03

P/S

3.44

EV/EBITDA

-7.07

DCF Value

$1.19

FCF Yield

-9.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

86.2%

Operating Margin

-44.8%

Net Margin

-46.8%

ROE

-59.1%

ROA

-34.0%

ROIC

-37.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$19.7M	$-13.0M	$—
Q4 null	$20.4M	$-4.2M	$—
FY null	$77.4M	$-38.4M	$—
Q3 null	$19.9M	$-8.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$9.67

Target (Median)

$9.00

Target Range

$8.00 - $12.00

1 Strong Buy3 Buy2 Hold0 Sell0 Strong Sell

CitigroupNeutral

2026-03-06

UBSBuy

2026-03-06

StifelBuy

2026-03-02

Piper SandlerOverweight

2026-01-05

UBSBuy

2025-12-23

Trading Activity

Insider Trades

View All

Bauerlein Alisonofficer: Chief Operating Officer

SellTue May 19

Rodberg Jamesofficer: Chief Financial Officer

SellThu Apr 09

HAYDEN JEREMY B.officer: Chief Legal Officer

SellThu Apr 09

Taylor Brentonofficer: EVP, Operations & R&D

SellFri Apr 03

Bauerlein Alisonofficer: Chief Operating Officer

SellFri Apr 03

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

Exchange

—

Beta

2.38

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

Peers

OMI